A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

Inclusion Criteria: * Best corrected visual acuity in the study eye between 5 and 7 letters inclusive using and ETDRS chart (Snellen equivalent of appx. 20/800 to 20/40. * Subfoveal choroidal neovascularization (CNV) due to AMD. * Total area of the lesion (including blood, neovascularization and scar/atrophy) must be ≤ 12 DA, of which at least 25% must be active CNV. * For patients with occult or non classic CNV; there must be the presence of subretinal hemorrhage (but still comprising no more than 50% of the lesion) and/or documented evidence of three or more lines of vision loss (ETDRS or equivalent) during the previous 12 weeks. * Clear ocular media and adequate pupillary dilatation to permit good stereo fundus photography for screening. * Intraocular pressure of 21 mm Hg or less. * Retinal thickness ≥ 250 μm by OCT. * Normal screening ERG * Normal ECG Exclusion Criteria: * PDT within 120 days prior to screening in the study eye. * Previous therapeutic radiation to the eye. * Any retinovascular disease or retinal degeneration other than AMD. * Serous pigment epithelial detachment without the presence of neovascularization. * Presence of pigment epithelial tears or rips. * Previous posterior vitrectomy or retinal surgery. * Any periocular infection in the past 4 weeks. * Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or previous use of these agents within 60 days of screening in the study eye. * Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90 days of screening. * Cataract surgery in the study eye within three months of screening. * Intraocular surgery in the study eye within three months of screening. * Presence of ocular infection in the study eye. * Presence of severe myopia (-8 diopters or greater) in the study eye. * Allergy to or prior significant adverse reaction to fluorescein. * Any major surgical procedure within one month of trial entry.